|Dyax Corp -- USA Stock|| |
null 38.41 38.41 9,223,372,036,855%
Executive VP, General Counsel and Secretary
Mr. Andrew Ashe is Executive Vice President and General Counsel of Dyax Corporationration since March 25 2013. He joined Dyax in 2003 and served as an attorney in our legal department until 2011 when he became our General Counsel. Mr. Ashe now manages the Companys legal intellectual property and compliance activities and also oversees the human resources facilities and information technology departments within Dyax. He also serves as the Companys Corporationrationrate Secretary. Prior to joining Dyax Mr. Ashe practiced law as a corporate attorney at Nutter McClennen Fish and Prince Lobel Tye two private law firms based in Boston Massachusetts. Previously he also worked as a specialist and senior options analyst at the American Stock Exchange in New York
Age: 47 EVP Since 2013
Ashe received his law degree from The George Washington School of Law and a Bachelors in Business Administration from the University of Massachusetts, Amherst.
Andrew Ashe Latest Insider Activity
The company has return on total asset (ROA)
of (0.06) %
which means that it has lost $0.06 on every $100 spent on asset. This is way below average.
The company currently holds 82.17 M in liabilities with Debt to Equity (D/E) ratio of 0.26 which may suggest the company is not taking enough advantage from borrowing. Dyax Corp has Current Ratio of 11.43 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Dyax Corporation, a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema and other plasmakallikreinmediated disorders. Dyax Corp (DYAX) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 124 people. Dyax Corp is listed under Business Services category by Fama And French industry classification.
Dyax Corp Leadership Team
|Thomas Kempner, Director|
|Henry Blair, Chairman|
|Jennifer Robinson, Director|
|James Fordyce, Director|
|Marc Kozin, Director, MBA|
|Mary Gray, Director, Ph.D|
|Paolo Pucci, Director, MBA|
|George Migausky, CFO, MBA|
|Andrew Ashe, EVP|
|Abbie Celniker, Director, Ph.D|
|Ron Cohen, Director|
|Burt Adelman, President, Ph.D|
|Gustav Christensen, CEO, MBA|
|Todd Bazemore, President|
|David McLachlan, Director|
Stock Performance Indicators